Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study-Reference-Cited by-同舟云学术

Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study

Published:2019 Issue:8 Volume:66 Page:745-752
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Shimoda Seiya¹,Sakamoto Wakana²,Hokamura Ayaka¹,Matsuo Yasuto³,Sekigami Taiji⁴,Ichimori Shinji⁵,Iwashita Shinsuke⁶,Ishii Norio⁷,Otsu Kae⁶,Yoshimura Ryohei⁸,Nishiyama Toshihiko⁹,Sakaguchi Masaji⁷,Nishida Kenro¹⁰,Araki Eiichi⁷

Affiliation:

1. Division of Food & Health Environmental Sciences, Faculty of Environmental and Symbiotic Sciences, Prefectural University of Kumamoto, Kumamoto 862-8502, Japan

2. Kumamoto General Hospital, Kumamoto 866-8660, Japan

3. Department of Medical Oncology & Diabetes, Saiseikai Kumamoto Hospital, Kumamoto 861-4193, Japan

4. Sekigami Clinic, Division of Medicine & Diabetes and Endocrine, Kumamoto 866-0824, Japan

5. Ueki Hospital, Kumamoto 861-0136, Japan

6. Kumamoto Rousai Hospital, Kumamoto 866-8533, Japan

7. Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan

8. Yoshimura Clinic, Kumamoto 861-8039, Japan

9. Sakurado-ri Clinic, Kumamoto 860-0832, Japan

10. Kumamoto Chuo Hospital, Kumamoto 862-0962, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.jstage.jst.go.jp/article/endocrj/66/8/66_EJ19-0179/_pdf

Reference26 articles.

1. 1 Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, et al. (2007) Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 357: 1716–1730.

2. 2 Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, et al. (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32: 193–203.

3. 3 Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, et al. (2015) New insulin glargine 300 Units·mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units·mL-1. Diabetes Care 38: 637–643.

4. 4 Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H (2012) Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 14: 944–950.

5. 5 Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, et al. (2012) Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 14: 859–864.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials;Frontiers in Endocrinology;2024-03-21

2. Clinical course of different long-acting insulin therapies—glargine U100, U300, degludec, and insulin degludec/insulin aspart—among Japanese patients with type 2 diabetes: a multicenter retrospective observational study (JDDM65 study);Endocrine Journal;2022

3. Comparative efficiency and safety of insulin degludec/aspart with insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials;Endocrine Journal;2022

4. Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis;Metabolites;2021-09-18

5. Low fasting glucose‐to‐estimated average glucose ratio was associated with superior response to insulin degludec/aspart compared with basal insulin in patients with type 2 diabetes;Journal of Diabetes Investigation;2021-08-24